Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Thursday 02 October, 2008

Lipoxen PLC

Lifetime Achievement Awards

RNS Number : 9100E
Lipoxen PLC
02 October 2008
 



Lipoxen Plc ('Lipoxen' or 'the Company')



Lipoxen Chief Scientific OfficerProfessor Gregory Gregoriadis, Awarded Two Lifetime Achievement Honours



London, UK, 02 October 2008 - Lipoxen PLC, (AIM:LPX) a biopharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and oncology drugs, today announces that the Company's Chief Scientific Officer and founderProfessor Gregory Gregoriadishas recently been presented with two lifetime achievement awards for his outstanding contributions to the advancement of drug and vaccine delivery and for his contributions to the pharmaceutical sciences. 


Professor Gregoriadis received the Journal of Drug Targeting Award for his exceptional lifelong contribution to the advancement of drug and vaccine delivery and was presented the honour at a special session of the British Pharmaceutical Conference in Manchester in September, together with a special issue of the Journal devoted to his work.


Based on his significant contribution to pharmaceutical sciences Professor Gregoriadis was also selected by the APS Fellowship Selection Committee for the award of Fellow of the Academy of Pharmaceutical Scientists, a decision which received the full support of the Board of Trustees of the Academy of Pharmaceutical Societies of Great Britain. 


Professor Gregoriadis laid the foundation of Lipoxen 11 years ago, in 1997 with the vision to build leadership in the drug and vaccine deliveryUnder his scientific leadership, the Company has grown extensively, went public in 2006, and now has two products in clinical development SuliXen, a long-acting human insulin and ErepoXen, long-acting EPO, with each addressing markets in excess of US$1 billion.


Commenting on the awardsProfessor Gregoriadis said, 'I am honoured and profoundly grateful to the highly respected Academy of Pharmaceutical Scientists and the Journal of Drug Targeting for these awards. They represent work initiated by myself in 1970 and then continued by Lipoxen and our talented collaborators over an 11-year span focused on one goal - the advancement of drug and vaccine delivery. With this recognition, we will continue to advance the area and move ahead to develop novel innovations which will benefit the healthcare industry'.




- Ends -



 Enquiries 


Lipoxen PLC


M. Scott Maguire, Chief Executive Officer

+44 (0)20 7691 3583 



Landsbanki Securities (UK) Limited (nominated adviser)


Shaun Dobson / Claes Spång 

+44 (0)20 7426 9000



Citigate Dewe Rogerson

+44 (0)20 7638 9571

David Dible / Heather Keohane




Notes to Editors

Further information on Lipoxen 


Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the development of high value differentiated biologicals, vaccines and oncology drugs. Products currently under development include improved formulations of important biologicals such as erythropoietin (EPO), G-CSF, insulin and Interferon-alpha. Lipoxen has two products in clinical development SuliXen, a long-acting human insulin and ErepoXen[R], long-acting EPO. These novel products, which are based on Lipoxen's proprietary PolyXen[R] technology, each address markets in excess of US$1 billion. 


Lipoxen's technology is designed to improve the stability, biological half-life and immunologic characteristics of therapeutic proteins naturally. Lipoxen has two further naturally-derived proprietary delivery technologies, ImuXen[R] and a related liposomal technology for the formulation of cytotoxic oncology drugs, which are being developed to enhance the efficacy and safety of various vaccines such as a multivalent Hepatitis B-E and pneumococcal vaccines, as well as a number of anti-cancer agents like paclitaxel. The Company's proprietary delivery technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India Limited (one of the world's leading vaccine companies, India's largest biotech company and a major shareholder in Lipoxen) and has license agreements in place with Baxter International and InterVet, a leading animal health company.


Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange in January 2006.


This announcement includes 'forward-looking statements' which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words 'targets', 'believes', 'estimates', 'expects', 'aims', 'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Among the important factors that could cause the Company's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to The Company's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUUGRWUUPRUMP